Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold

Maximilian Koch, Johannes S de Jong, Jürgen Glatz, Panagiotis Symvoulidis, Laetitia E Lamberts, Arthur L.L. Adams, Mariëtte E G Kranendonk, Anton G T Terwisscha van Scheltinga, Michaela Aichler, Liesbeth Jansen, Jakob de Vries, Marjolijn N Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D Linssen, Esther de Boer, Bert van der Vegt, Wouter B Nagengast, Sjoerd G. Elias, Sabrina OliveiraArjen J. Witkamp, Willem P.Th M. Mali, Elsken Van der Wall, Beatriz P Garcia-Allende, Paul J. van Diest, Elisabeth G E de Vries, Axel Walch, Gooitzen M van Dam, Vasilis Ntziachristos

Research output: Chapter in Book/Report/Conference proceedingConference contributionAcademicpeer-review

Fingerprint

Dive into the research topics of 'Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold'. Together they form a unique fingerprint.

Immunology and Microbiology